
Studying a galaxy far, far away could become easier with help from AI, says researcher
As part of Youssef Zaazou's master's of science, he developed an AI-based image-processing technique that generates predictions of what certain galaxies may look like in a given wavelength of light.
"Think of it as translating galaxy images across different wavelengths of light," Zaazou told CBC News over email.
He did this by researching past methods for similar tasks, adapting current AI tools for his specific purposes, finding and curating the right dataset to train the models, along with plenty of trial and error.
"Instead of … having to look at an entire region of sky, we can get predictions for certain regions and figure out, 'Oh this might be interesting to look at,'" said Zaazou. "So we can then prioritize how we use our telescope resources."
Zaazou recently teamed up with his supervisors Terrence Tricco and Alex Bihlo to co-author a paper on his research in The Astrophysical Journal, which is published by The American Astronomical Society.
Tricco says this research could also help justify allocation of high-demand telescopes like the Hubble Space Telescope, which has a competitive process to assign its use.
A future for AI in astronomy
Both Tricco and Zaazou emphasised the research does not use AI to replace current methods but to augment them.
Tricco says that Zaazou's findings have the potential to help guide future telescope development, and predict what astronomers might expect to see, making for more efficient exploration.
Calling The Astrophysical Journal the "gold standard" for astronomy journals in the world, Tricco hopes the wider astronomical community will take notice of Zaazou's findings.
"We want to have them be aware of this because as I was mentioning, AI, machine learning, and physics, astronomy, it's still very new for physicists and for astronomers, and they're a little bit hesitant about these tools," said Tricco.
Tricco praised the growing presence of space research in general at Memorial University.
"We are here, we're doing great research," he said.
He added growing AI expertise is also transferable to other disciplines.
"I think that builds into our just tech ecosystem here as well."
'Only the beginning'
Though Zaazou's time as a Memorial University student is over, he hopes to see research in this area continue to grow.
"I'm hoping this is the beginning of further research to be done," he said.
Though Zaazou described his contribution to the field as merely a "pebble," he's happy to have been able to do his part.
"I'm an astronomer. And it just feels great to be able to say that and to be able to have that little contribution because I just love the field and I'm fascinated by everything out there," said Zaazou.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
an hour ago
- Globe and Mail
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
AstraZeneca AZN has unveiled a sweeping $50 billion investment plan in the United States, to be executed by 2030. The initiative is expected to significantly generate skilled jobs across the country and support the development of advanced therapies for patients in the United States and beyond. AstraZeneca's investment in U.S. manufacturing and R&D aligns with its broader strategy to expand domestic production in response to ongoing tariff pressures under President Donald Trump. This move aims to strengthen U.S. manufacturing and help lower healthcare costs for the people of the country. The centerpiece of the announcement is a new multi-billion-dollar manufacturing facility to be set up in Virginia, the company's largest single investment in a facility to date. It will focus on producing drug substances for AstraZeneca's pipeline of weight management and metabolic therapies. These include oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The site will manufacture small molecules, peptides and oligonucleotides, and feature advanced technologies such as AI, automation and data analytics to streamline operations. The project builds on a previously announced $3.5 billion investment in late 2024. Year to date, AstraZeneca's shares have gained 4.9% against the industry 's 2.2% decline. In addition to the Virginia facility, AstraZeneca's broader investment will support the expansion of several key R&D and manufacturing hubs across the United States. Plans include expanding the Gaithersburg R&D campus in Maryland, establishing a new research center in Cambridge, Massachusetts and building next-generation cell therapy manufacturing sites in Maryland and California. Other expansions are set for manufacturing sites in Indiana and Texas, along with new facilities to support clinical studies and the development of novel medicines. These combined efforts are aligned with AstraZeneca's long-term financial goals, with the target of $80 billion in total revenues by 2030, half of which it anticipates generating from the U.S. market. Despite being headquartered in the United Kingdom, the United States is AstraZeneca's largest market, hosting 19 sites and more than 18,000 employees, with a total economic impact of $20 billion in 2024. Currently, 42% of the company's total revenues are generated from the U.S. market. Pharma Giants Ramp Up Domestic Manufacturing The uncertainty around tariffs and trade production measures has muted economic growth. Earlier this month, President Trump once again threatened to impose heavy tariffs, as high as 200%, on pharmaceutical imports. President Trump's repeated threats to impose tariffs on pharmaceutical imports are aimed at pushing the U.S. pharma companies to shift production back to the country, primarily from Europe and Asia. The U.S. President stated that drugmakers have about one year to one and a half years to bring production back to the country before the new tariffs are imposed. We note that most pharma/biotech bigwigs have already announced plans to ramp up manufacturing in the country. In February 2025, Eli Lilly and Company LLY announced plans to bolster its domestic drug production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States. This move will bring LLY's manufacturing investments in the United States to more than $50 billion since 2020. Among these, three will focus on manufacturing active pharmaceutical ingredients, reshoring critical capabilities of small molecule chemical synthesis and further strengthening Lilly's supply chain. In March 2025, Johnson & Johnson JNJ announced an investment of more than $55 billion in the United States (over the next four years) in manufacturing, R&D and technology. Per JNJ, this represents a 25% increase in investment compared with the previous four years and builds upon its already increased investments resulting from the passage of the 2017 Tax Cuts & Jobs Act. Swiss pharma giant Novartis NVS has also announced a planned $23 billion investment over five years in the U.S.-based infrastructure. The company intends to manufacture all key drugs for its patients in the country. NVS will build four new manufacturing facilities in three states. Among these, three will be engaged in biologics drug substances, drug products, device assembly and packaging, and one will make chemical drug substances, oral solid dosage forms and packaging. AZN's Zacks Rank and Stocks to Consider AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report


CBC
an hour ago
- CBC
A Regina study wants to reduce Saskatchewan's nation-leading rates of HIV, hepatitis C and syphilis
A Regina project called 3 Infections, 1 Fight is setting up a first-of-its-kind study in Canada.


Cision Canada
5 hours ago
- Cision Canada
From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits
VANCOUVER, BC, July 22, 2025 /CNW/ -- USA News Group News Commentary – The AI revolution in healthcare is fully underway, with the potential to save lives and money, but there's still more to come. Healthcare startups are already figuring out how to implement AI to multiply their patients, and chase profits, to the benefit of investors. More Americans than ever are utilizing AI to diagnose their health issues, as the adoption of AI tools is becoming the norm among medical professionals. Now the developers of these game-changing technologies are overcoming regulatory barriers and moving closer to implementation of their solutions in the real world. Among the players that are moving closer to major milestones include Avant Technologies, Inc. (OTCQB: AVAI), Agenus Inc. (NASDAQ: AGEN), Clover Health Investments, Corp. (NASDAQ: CLOV), Zimmer Biomet Holdings, Inc. (NYSE: ZBH), and Monogram Technologies Inc. (NASDAQ: MGRM). Currently, the AI in healthcare sector projected to surpass $110 billion by 2030. However, according to Accenture, artificial intelligence could unlock an additional $461 billion in value across healthcare by 2035—on top of a sector already projected to surpass $2.26 trillion. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech are continuing to raise visibility for their AI-powered diagnostic platform, with Ainnova CEO Vinicio Vargas recently featured as a speaker at Roche's"Macular Spectacular" Ophthalmology Conference in Cartagena, Colombia. The event brought together leading voices in visual health from across Latin America, with discussions focused on advancing patient outcomes through AI innovation. Vargas, who also sits on the board of Ai-nova Acquisition Corp. (AAC), presented Vision AI as a transformative tool to expand access to early diabetic retinopathy screening and reduce preventable blindness throughout the region. Vargas also highlighted a Q4 2024 alliance with Roche and prepaid‑health‑plan provider Salud 360 that is piloting Vision AI among high‑risk diabetic patients; if successful, the program will be rolled out in the United States, Canada, and Europe through Ai ‑ nova Acquisition Corp. (AAC), which holds worldwide rights to Ainnova's technology portfolio . This momentum builds on a recent regulatory breakthrough in the U.S. market. Avant and Ainnova recently completed a key pre-submission meeting with the FDA for Vision AI, the companies' flagship diagnostic platform for diabetic retinopathy and other retinal diseases. "We're truly excited about this next phase," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. "We're getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous—comparing our AI-based retinal screening to the readings of three retinologists. The July 15 meeting marked a critical step toward securing 510(k) clearance for Vision AI. The FDA session offered clear feedback on study design, site selection, and execution strategy—enabling Ainnova and its clinical trial partner, Fortrea, to finalize preparations for U.S.-based trials. "This milestone not only brings us closer to validating our platform in the world's largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera," added Vargas. "We believe will [it] be a game changer—making diabetic retinal screenings faster, more accessible, and available from virtually any point of care." While regulatory efforts advance in the U.S., the company has already launched a groundbreaking chronic care model across Latin America. The program, now live through Grupo Dökka's Fischel and La Bomba pharmacy chains, offers free, walk-in retinal risk assessments—delivering real-time AI results and connecting at-risk patients directly with clinics and specialists. Over 30% of diabetics develop diabetic retinopathy, a leading cause of preventable blindness. Vision AI offers early, low-cost screening without the need for an ophthalmologist onsite. The model has gained support from pharmacies, insurers, and pharmaceutical partners—demonstrating real traction across the healthcare value chain. Avant' s role in these efforts continues to grow. Through Ai-nova Acquisition Corp., which it co-founded and structured, Avant maintains global licensing rights to Ainnova's platform and stands to benefit from both U.S. and international commercialization. The Latin American pilot programs are already generating momentum, with U.S. trials positioned to unlock a vastly larger market. The company is also preparing a standalone venture to house a potential therapeutic candidate for diabetes—bringing leadership, data, and IP into one streamlined structure for diagnostics and treatment alike. Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova's future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer's, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers. A structural simplification may be on the horizon as well. A previously announced non-binding LOI remains active for Avant to acquire 100% of Ainnova Tech —potentially consolidating all IP, leadership, and commercial rights under one public entity. Such a move would give investors pure-play exposure to this fast-evolving tech stack, while deepening operational alignment between the firms. Agenus Inc. (NASDAQ: AGEN) has partnered with AI biotech firm Noetik to develop predictive biomarkers for its cancer immunotherapy combo BOT/BAL. "At Agenus, we are committed to transforming cancer care through scientific innovation and next-generation immunotherapies," said Dr. Garo Armen, Chairman and CEO of Agenus. "This collaboration with Noetik enables us to harness cutting-edge AI to better understand patient biology and tailor treatments more precisely." By using Noetik's advanced "virtual cell" models trained on massive tumor datasets, the collaboration aims to identify which patients are most likely to benefit from treatment. This could improve clinical trial outcomes and accelerate personalized cancer care using AI-driven insights Clover Health Investments, Corp. (NASDAQ: CLOV) recently launched a new pharmacy pilot program across New Jersey in partnership with IPC's iCare+ network. The initiative enables local pharmacies to use AI tools and real-time data to help seniors manage medications and reduce hospital visits. "This is more than a new program—it's a new model for how we support our New Jersey members," said Jamie Reynoso, CEO of Medicare Advantage at Clover Health. "By working with the pharmacists who are already embedded in our communities, we can deliver better care, deliver amazing customer experiences and support the independent businesses that keep New Jersey strong." It's part of Clover's strategy to deliver more personal, community-based healthcare while supporting independent pharmacies Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has entered a definitive agreement to acquire Monogram Technologies Inc. (NASDAQ: MGRM) for approximately US$177 million in cash, with additional milestone-based payments up to US$12.37 per share. " Monogram's technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation," said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. "Upon closing, our customer-centric portfolio will consist of the most comprehensive and flexible technology ecosystem to support the varying preferences of a vast array of surgeons – now and into the future. With Monogram's proprietary technology, Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery." The acquisition adds Monogram's semi- and fully autonomous orthopedic robotics to Zimmer Biomet's ROSA® platform, aiming to create the most comprehensive robotics suite in the orthopedic space. Monogram's FDA-cleared knee arthroplasty robot is expected to commercialize in 2027, with a fully autonomous version in development. "Since our inception, we have been singularly focused on advancing orthopedic robotics with technology designed to safely, efficiently and accurately support surgeons with total knee arthroplasty," said Benjamin Sexson, CEO of Monogram. "We are thrilled by the opportunity to add our technology to Zimmer Biomet's leading portfolio of surgical robotics, navigation solutions and trusted implants and to benefit from their deep industry expertise and global scale." Zimmer Biomet expects the deal to be accretive by 2028, supporting long-term growth in the high-demand surgical robotics market. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.